Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ichorion Therapeutics
New York, New York, United Statesichoriontx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ichorion developed a pipeline of genetically-targeted therapies for rare pediatric and orphan metabolic disorders. At acquisition, its lead program targeted DGUOK for mitochondrial diseases and was in preclinical development. Two programs had received Rare Pediatric Disease Designation and were eligible for Priority Review Vouchers upon approval. The company’s approach included leveraging the 505(b)(2) regulatory pathway to potentially expedite development timelines
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Partnerships
No major external partnerships disclosed prior to acquisition; now part of Cerecor/Avalo’s portfolio.
Beyond the preview
Go deeper on Ichorion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichorion Therapeutics.